Review Article

Role of Catheter Ablation in Arrhythmogenic Right Ventricular Dysplasia

This paper has also been published in the First International Symposium on Arrhythmogenic Right Ventricular Dysplasia

Johnson Francis, MBBS, MD, DM*, Guy Fontaine, MD, PhD, FACC, FAHA, FESC†

*Department of Cardiology, Medical College, Calicut, Kerala, India
†Service de rythmologie, Institut de cardiologie, hopital La Pitié-Salpetriere, Paris, France

Address for correspondence: Dr. Johnson Francis, MD,DM, Associate Professor of Cardiology, Medical College Calicut, Kerala, India. PIN: 673 008. Email: ipej2004@gmail.com

Abstract

Arrhythmogenic right ventricular dysplasia-cardiomyopathy is a disorder characterized by frequent ventricular tachycardia originating from the right ventricle and fibro-fatty replacement of right ventricular myocardium. Though the disorder was originally described during surgical ablation of refractory ventricular tachycardia, catheter ablation of tachycardia is one of the options for patients not responding to anti arrhythmic agents. Direct current fulguration was used in the initial phase followed by radiofrequency catheter ablation. In the present day scenario, all patients with risk for sudden cardiac death should receive an implantable cardioverter defibrillator. Radiofrequency catheter ablation remarkably reduces the frequency of defibrillator therapies. Direct current fulguration can still be considered in cases when radiofrequency ablation fails, though it requires higher expertise, general anesthesia and carries a higher morbidity. Newer mapping techniques have helped in identification of the site of ablation. In general, the success rate of ablation in arrhythmogenic right ventricular dysplasia is less than in other forms of right ventricular tachycardias like right ventricular outflow tract tachycardia.

Key Words: Arrhythmogenic Right Ventricular Dysplasia; Ventricular Tachycardia; Catheter Ablation

Introduction

Arrhythmogenic right ventricular dysplasia-cardiomyopathy (ARVD) is a disorder characterized by fibro-fatty replacement of the right ventricular myocardium, frequent ventricular tachycardia originating from the right ventricle and right heart failure. It was originally described by Fontaine et al during surgical ablation of refractory ventricular tachycardia1. The first case of ARVD underwent surgical ablation in October 1973 with a simple incision made at the site of origin of ventricular tachycardia (VT). This was successful to prevent recurrence of the arrhythmia and contributed to the identification of this disease2. The first clinical series of 24 adult cases was published by Marcus et al in19823. The refractory
ventricular arrhythmias of ARVD has always been a challenge for the clinician. Catheter ablation has been tried in spite of the justifiable fear of perforation of the dysplastic ventricle. This short review aims at bringing together the available literature on catheter ablation in ARVD.

**Therapeutic Options in ARVD**

Though historically the original description of ARVD was during surgical ablation, pharmacological therapy was the initial mode of treatment in most cases. Surgical ablation by right ventricular disconnection was resorted to in resistant cases. Peroperative cryoablation of 8 cases were reported by Isobe from Japan. None of the eight patients died during a mean follow up of 3.25 year. VT recurred in two patients and a new VT was seen in another patient. Endocavitary electrode catheter ablation using direct current shocks of 100 to 320 J was another mode of therapy which was tried in that period. Nowadays, implantable cardioverter defibrillators (ICD) are being recommended more often to cover the risk of sudden cardiac death (SCD) in ARVD. Even then, patients may need pharmacological therapy to reduce the number of shocks. Patients having recurrent sustained VT while on optimal medical therapy are candidates for catheter ablation.

**Catheter Ablation in ARVD**

The initial reports on catheter ablation in ARVD were using direct current fulguration. One of the earliest series of fulguration in ARVD was that of 13 patients who were treated with shocks ranging from 160 to 280 J. Single or multiple shocks were required in up to three sessions. There were two deaths and four of the 11 survivors required antiarrhythmic treatment following the fulguration therapy. The mean follow up was 45 months. With the advent of radiofrequency catheter ablation, direct current fulguration went out of vogue. Fontaine et al has suggested that fulguration should still be tried if radiofrequency ablation is not successful. In their 16 year experience of ablation in ARVD, the effectiveness of radiofrequency was less than 40% in the first session. At same time, fulguration is effective in the same session after ineffective radiofrequency ablation. Complications have disappeared since the use of soft and steerable ablation catheters. This work also classifies thoroughly the results of VT ablation alone and in combination with antiarrhythmic drugs, definition of relapses, etc... But the disadvantage of fulguration is that it requires expertise, general anesthesia and more than one session in half the patients.

**Radiofrequency Catheter Ablation**

Radiofrequency catheter ablation for ARVD has been in use since early nineties. It has been suggested that only patients with focal dysplasia are potential candidates for ablation. Entrainment mapping can be used to characterize reentry circuits in ARVD to guide ablation. The concept of concealed entrainment was first reported by Fontaine et al in 1989. This paper stresses the identification of the zone of slow conduction. The concept was originally found in a patient with ARVD. It was later extended to other forms of chronic VT (post-myocardial infarction), and more recently is used as a marker of the reentry pathway in re-entrant supraventricular tachycardias. Ellison et al mapped 19 VTs in 5 patients with ARVD. Radiofrequency current was applied to the 58 sites where pacing entrained the VT to assess acute termination, with only 22% success. Eight of the 19 VTs were rendered noninducible and three were modified to a longer cycle length. In two patients ablation at a single site abolished two VTs. Harada et al did entrainment mapping in 8 VTs in 7 patients with ARVD. Radiofrequency applications were done at 31 sites identified by mapping and terminated 7 of...
Endocardial mapping can detect abnormal fragmented electrograms with delayed potentials. Pacemapping confirms the ablation site by producing a QRS morphology identical to the clinical VT. Recently non-contact mapping has been used to guide catheter ablation in ARVD. The endocardial exit point was defined in all three ARVD patients and the diastolic pathway (earliest endocardial diastolic activity) was identified in one of them. Catheter ablation was completely effective in only one of the three. Reithmann et al used electroanatomic mapping of right ventricular endocardial activation as a guide for catheter ablation in patients with ARVD. Both electroanatomic mapping and entrainment procedures were performed in 5 patients. Endocardial mapping during tachycardia demonstrated a focal activation pattern with radial spreading of activation from the site of earliest activation. The sites of earliest activation were in an aneurysmal outflow tract in two patients, at the border of aneurysms near the tricuspid annulus in two patients and at the apex of the right ventricle in one. Entrainment mapping showed that these were the exit sites of the reentrant circuits. The clinical VTs were noninducible in 4 of the 5 patients after catheter ablation. During a mean follow up of 7 months, the frequency of ICD therapies came down from 49 + 61 episodes per month to 0.3 + 0.5 episodes per month.

Three dimensional Real-time Positioning Management System (RPM) has also been used for guiding ablation in ARVD. RPM uses sonomicrometry to determine the spatial location of the ablation catheter relative to two reference catheters positioned in the right atrium and right ventricle.

O'Donnell et al have highlighted the electrophysiological differences between patients with ARVD and right ventricular outflow tract tachycardia (RVOT VT). Though radiofrequency ablation is the first line treatment for symptomatic RVOT VT, the role is limited in ARVD. In their study they compared 33 patients with RVOT VT and 17 patients with ARVD. Re-entry was the mechanism of tachycardia in 80% of the ARVD group while 97% of RVOT VT had features of triggered automaticity. Partial or complete success was obtained only in 71% of patients with ARVD while complete success was obtained in 97% of RVOT VT. The recurrence rate was 48% in ARVD and 6% in RVOT VT.

Ablation of ventricular tachycardias in ARVD still remains a clinical challenge, though more and more cases are being reported in the literature.

References

1. Fontaine G, Guiraudon G, Frank R. Stimulation studies and epicardial mapping in VT: Study of mechanisms and selection for surgery. In: Hulbertus HE, Editor. Reentrant arrhythmias. Lancaster, PA: MTP Publishers, 1977; 334-350; Cited in Brugada J, Mont L, Brugada R. Arrhythmogenic dysplasia of the right ventricle. Rev Esp Cardiol. 1997;50:541-7.

2. Fontaine G. The ablative techniques from surgery to catheter ablation in the treatment of cardiac arrhythmias: a 20 year experience. Acta Cardiol. 1995;50:467-8.

3. Right ventricular dysplasia: a report of 24 adult cases. Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, Grosgeot Y. Circulation. 1982 Feb;65(2):384-98.

4. Ott DA, Garson A, Cooley DA, McNamara DG. Definitive operation for refractory cardiac tachyarrhythmias in children. J Thorac Cardiovasc Surg. 1985;90:681-9.

5. Isobe F. Surgical treatment of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia and their long follow-up results. Nippon Kyobu Geka Gakkai Zasshi. 1990;38:2017-23.
6. Fontaine G, Tonet JL, Frank R, Touzet I, Farenq G, Dubois-Rande JL, Baraka M, Abdelali S, Grosgogeat Y. Treatment of resistant ventricular tachycardia with endocavitary ablation combined with anti-arrhythmic agents. Arch Mal Coeur Vaiss. 1986;79:1152-9.

7. Baraka M, Tonet J, Fontaine G, Abdelali S, Menezes-Falcao L, Frank R, Grosgogeat Y. Rhythm and conduction disorders immediately after ventricular fulguration. Arch Mal Coeur Vaiss. 1988;81:269-75.

8. Haissaguerre M, Warin JF, Lemetayer P, Guillem JP, Blanchot P. Treatment of refractory ventricular tachycardia using cumulative high-energy fulguration. Arch Mal Coeur Vaiss. 1988;81:879-860.

9. Fontaine G, Frank R, Rougier I, Tonet JL, Gallais Y, Farenq G, Lascault G, Lilamand M, Fontaliran F, Chomette G, et al. Electrode catheter ablation of resistant ventricular tachycardia in arrhythmogenic right ventricular dysplasia: experience of 13 patients with a mean follow-up of 45 months. Eur Heart J. 1989 Sep;10 Suppl D:74-81.

10. Fontaine G, Tonet J, Gallais Y, Lascault G, Hidden-Lucet F, Aouate P, Halimi F, Poulain F, Johnson N, Charfeddine H, Frank R. Ventricular tachycardia catheter ablation in arrhythmogenic right ventricular dysplasia: a 16-year experience. Curr Cardiol Rep. 2000 Nov;2(6):498-506.

11. Borggrefe M, Willems S, Chen X, Hindricks G, Haeverkamp W, Martinez-Rubio A, Hief C, Shenasa M, Breithardt G. Catheter ablation of ventricular tachycardia using radiofrequency current. Herz. 1992;17:171-8.

12. Peters S. Right ventricular cardiomyopathy: diffuse dilatation, focal dysplasia or biventricular disease. Int J Cardiol. 1997 ;62:63-7.

13. Fontaine G, Frank R, Tonet J, Grosgogeat Y. Identification of a zone of slow conduction appropriate for VT ablation: theoretical and practical considerations. Pacing Clin Electrophysiol. 1989;12:262-7.

14. Ellison KE, Friedman PL, Ganz LI, Stevenson WG. Entrainment mapping and radiofrequency catheter ablation of ventricular tachycardia in right ventricular dysplasia. J Am Coll Cardiol. 1998 ;32:724-8.

15. Harada T, Aonuma K, Yamauchi Y, Igawa M, Hachiya H, Oh JC, Tomita Y, Suzuki F, Nakagawa T. Catheter ablation of ventricular tachycardia in patients with right ventricular dysplasia: Identification of target sites by entrainment mapping techniques. Pacing Clin Electrophysiol. 1998 ;21:2547-50.

16. Kusano KF, Emori T, Morita H, Ohe T. Ablation of ventricular tachycardia by isolating the critical site in a patient with arrhythmogenic right ventricular cardiomyopathy. J Cardiovasc Electrophysiol. 2000;11:102-5.

17. Della Bella P, Pappalardo A, Riva S, Tondo C, Fassini G, Trevisi N. Non-contact mapping to guide catheter ablation of un tolerated ventricular tachycardia. Eur Heart J. 2002;23:742-52.

18. Reithmann C, Hahnefeld A, Remp T, Dorwarth U, Dugas M, Steinbeck G, Hoffmann E. Electroanatomic mapping of endocardial right ventricular activation as a guide for catheter
ablation in patients with arrhythmogenic right ventricular dysplasia. Pacing Clin Electrophysiol. 2003;26:1308-16.

19. de Groot NM, Schalij MJ, van der Wall EE. Area ablation of ventricular tachycardia in a patient with arrhythmogenic right ventricular cardiomyopathy. Heart. 2003;89:703.

20. O'Donnell D, Cox D, Bourke J, Mitchell L, Furniss S. Clinical and electrophysiological differences between patients with arrhythmogenic right ventricular dysplasia and right ventricular outflow tract tachycardia. Eur Heart J. 2003;24:801-10.

21. Noda T, Suyama K, Shimizu W, Satomi K, Otomo K, Nakagawa E, Kurita T, Aihara N, Kamakura S. Ventricular tachycardia associated with bidirectional reentrant circuit around the tricuspid annulus in arrhythmogenic right ventricular dysplasia. Pacing Clin Electrophysiol. 2003;26:2050-1.

22. Zou J, Cao K, Yang B, Chen M, Shan Q, Chen C, Li W, Haines DE. Dynamic substrate mapping and ablation of ventricular tachycardias in right ventricular dysplasia. J Interv Card Electrophysiol. 2004;11:37-45.

23. Lacroix D, Lions C, Klug D, Prat A. Arrhythmogenic right ventricular dysplasia: catheter ablation, MRI, and heart transplantation. J Cardiovasc Electrophysiol. 2005;16:235-6.